<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
<channel>
                    <title>Rheumatology</title>
            <link>https://medicalxpress.com/rheumatology-news/</link>
            <language>en-us</language> 
            <description>Latest medical news and research in Rheumatology</description>

                            <item>
                    <title>Blocking receptor signals can help treat fibrosis</title>
                    <description>In an investigator-initiated trial, researchers have shown that inhibiting the cytokines IL-4 and IL-13 can prevent fibrosis in the skin disease localized scleroderma. These findings could pave the way for the prevention and treatment of other fibrotic conditions. The study &quot;Interleukin 4 receptor-α blockade in localised scleroderma: a phase II proof-of-concept study&quot; was published in the journal Annals of the Rheumatic Diseases.</description>
                    <link>https://medicalxpress.com/news/2026-11-blocking-receptor-fibrosis.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Nov 2026 10:00:01 EST</pubDate>
                    <guid isPermaLink="false">news714304182</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/working-model-for-inte.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New evidence questions benefits of turmeric for knee arthritis</title>
                    <description>A new Cochrane review has found that turmeric supplements may provide little or no clinically important pain relief for people with knee osteoarthritis, challenging conclusions from earlier research that suggested a benefit. The work appears in the Cochrane Database of Systematic Reviews.</description>
                    <link>https://medicalxpress.com/news/2026-11-evidence-benefits-turmeric-knee-arthritis.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 20:00:05 EST</pubDate>
                    <guid isPermaLink="false">news714204284</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/turmeric.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Morphea linked to higher risk for cancer</title>
                    <description>Morphea is associated with excess cancer incidence, according to a study published online Nov. 11 in JAMA Dermatology.</description>
                    <link>https://medicalxpress.com/news/2026-11-morphea-linked-higher-cancer.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 18:20:01 EST</pubDate>
                    <guid isPermaLink="false">news714236581</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/morphea.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Brepocitinib yields improvements in cutaneous sarcoidosis</title>
                    <description>For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida.</description>
                    <link>https://medicalxpress.com/news/2026-11-brepocitinib-yields-cutaneous-sarcoidosis.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 17:20:12 EST</pubDate>
                    <guid isPermaLink="false">news714218774</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/brepocitinib-yields-im.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>CAR T-cell therapy shows promise for patients with lupus</title>
                    <description>For patients with systemic lupus erythematosus (SLE), chimeric antigen receptor T-cell (CAR T-cell) therapy is associated with consistent reductions in disease activity, according to research presented at the annual meeting of the American College of Rheumatology (ACR Convergence 2026), held from Nov. 6 to 11 in Orlando, Florida.</description>
                    <link>https://medicalxpress.com/news/2026-11-car-cell-therapy-patients-lupus.html</link>
                    <category></category>
                    <pubDate>Mon, 16 Nov 2026 15:00:03 EST</pubDate>
                    <guid isPermaLink="false">news714057837</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/acr-car-t-cell-therapy.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Sustained clinical responses seen with neuroimmune modulation for rheumatoid arthritis</title>
                    <description>Twenty-four-month data show sustained clinical responses for patients receiving neuroimmune modulation therapy for rheumatoid arthritis (RA), according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida.</description>
                    <link>https://medicalxpress.com/news/2026-11-sustained-clinical-responses-neuroimmune-modulation.html</link>
                    <category></category>
                    <pubDate>Fri, 13 Nov 2026 08:20:06 EST</pubDate>
                    <guid isPermaLink="false">news713772003</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/rheumatoid-arthritis-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Blood thinner could offer a new way to treat osteoarthritis</title>
                    <description>Osteoarthritis is the most common form of joint disease, a condition that causes joints to become painful and stiff. It can happen to any joint when the cartilage cushioning the ends of bones breaks down or wears away. Currently, there are no approved drugs to slow or stop the underlying disease. But there is a promising development from an unexpected quarter—a blood thinner.</description>
                    <link>https://medicalxpress.com/news/2026-11-blood-thinner-osteoarthritis.html</link>
                    <category></category>
                    <pubDate>Thu, 12 Nov 2026 12:00:13 EST</pubDate>
                    <guid isPermaLink="false">news713704879</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/blood-thinner-could-of.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Head-to-head trial reveals better immune-dampening drug for psoriatic arthritis</title>
                    <description>A newer immune-dampening drug appears to effectively quell pain and swelling in joints affected by psoriatic arthritis, a new study says. The injectable drug bimekizumab (Bimzelx) eased psoriatic arthritis for more patients than a slightly older drug from its same class, risankizumab (Skyrizi), researchers reported at the American College of Rheumatology (ACR) conference in Orlando, Florida.</description>
                    <link>https://medicalxpress.com/news/2026-11-trial-reveals-immune-dampening-drug.html</link>
                    <category></category>
                    <pubDate>Thu, 12 Nov 2026 10:20:22 EST</pubDate>
                    <guid isPermaLink="false">news713699103</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/joint-pain.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Digitally supported care model improves serum urate target attainment in gout</title>
                    <description>For patients with gout, a physician-supervised treat-to-target (T2T) care model improves serum urate (SUA) target attainment, according to a study published online Nov. 4 in Arthritis &amp; Rheumatology.</description>
                    <link>https://medicalxpress.com/news/2026-11-digitally-serum-urate-gout.html</link>
                    <category></category>
                    <pubDate>Tue, 10 Nov 2026 18:00:02 EST</pubDate>
                    <guid isPermaLink="false">news713545501</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2022/gout.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Lung ultrasound predicts progression of interstitial lung abnormalities in rheumatoid arthritis</title>
                    <description>Lung ultrasound (LUS) can predict radiologic progression of interstitial lung abnormalities (ILAs) in patients with rheumatoid arthritis (RA), according to a study published in the November issue of Arthritis &amp; Rheumatology.</description>
                    <link>https://medicalxpress.com/news/2026-11-lung-ultrasound-interstitial-abnormalities-rheumatoid.html</link>
                    <category></category>
                    <pubDate>Tue, 10 Nov 2026 17:40:01 EST</pubDate>
                    <guid isPermaLink="false">news713545201</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2018/1-lungs.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Few meet major clinical response criteria after treatment escalation for lupus</title>
                    <description>For patients with systemic lupus erythematosus (SLE), fewer than one-quarter meet criteria for major clinical response (MCR) after treatment escalation, with Black patients less likely to meet MCR criteria than white patients, according to a study published online Nov. 2 in The Lancet Rheumatology.</description>
                    <link>https://medicalxpress.com/news/2026-11-major-clinical-response-criteria-treatment.html</link>
                    <category></category>
                    <pubDate>Mon, 09 Nov 2026 18:10:06 EST</pubDate>
                    <guid isPermaLink="false">news713468044</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2020/5-patient.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials</title>
                    <description>For people with painful knee osteoarthritis (OA) who are overweight or have obesity, everyday activities such as walking, climbing stairs and standing up from a chair can be difficult. In two Northwestern University–led Phase III clinical trials involving more than 1,000 participants combined, those taking the highest dose of retatrutide, a new experimental weight-loss injectable drug, lost about one-quarter of their body weight on average.</description>
                    <link>https://medicalxpress.com/news/2026-11-experimental-weight-loss-drug-eases.html</link>
                    <category></category>
                    <pubDate>Sun, 08 Nov 2026 11:30:01 EST</pubDate>
                    <guid isPermaLink="false">news713177942</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/painful-knee.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New trial of AI phone assistant to monitor patients with long-term illness</title>
                    <description>An AI assistant that conducts telephone consultations with patients is being trialed in the NHS to help clinicians monitor people with long-term illness. In the trial phase, the virtual assistant, called Dora Care, is designed to deliver safe and empathetic phone calls for people with osteoporosis—a bone-weakening condition that affects 3.5 million people in the U.K., particularly women and those over 50.</description>
                    <link>https://medicalxpress.com/news/2026-11-trial-ai-patients-term-illness.html</link>
                    <category></category>
                    <pubDate>Fri, 06 Nov 2026 22:20:01 EST</pubDate>
                    <guid isPermaLink="false">news713180996</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/elderly-woman-on-telep.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Knee osteoarthritis: Symptoms, diagnosis and treatment</title>
                    <description>Knee osteoarthritis (OA) is the most common type of arthritis, affecting about 528 million adults worldwide.</description>
                    <link>https://medicalxpress.com/news/2026-11-knee-osteoarthritis-symptoms-diagnosis-treatment.html</link>
                    <category></category>
                    <pubDate>Wed, 04 Nov 2026 22:00:01 EST</pubDate>
                    <guid isPermaLink="false">news713009160</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/knee.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Postoperative complications elevated for patients with systemic lupus erythematosus</title>
                    <description>Patients with systemic lupus erythematosus (SLE) have an increased risk for postoperative complications, according to a study published online Oct. 9 in Rheumatology International.</description>
                    <link>https://medicalxpress.com/news/2026-11-postoperative-complications-elevated-patients-lupus.html</link>
                    <category></category>
                    <pubDate>Tue, 03 Nov 2026 13:40:08 EST</pubDate>
                    <guid isPermaLink="false">news712933519</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2023/operating-room-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Treatment satisfaction higher for patients with rheumatoid arthritis choosing their own treatment</title>
                    <description>For patients with rheumatoid arthritis (RA), those choosing their own treatment have higher treatment satisfaction, better treatment retention and fewer reported adverse events, according to a study published online Oct. 27 in RMD Open.</description>
                    <link>https://medicalxpress.com/news/2026-11-treatment-satisfaction-higher-patients-rheumatoid.html</link>
                    <category></category>
                    <pubDate>Tue, 03 Nov 2026 13:20:06 EST</pubDate>
                    <guid isPermaLink="false">news712933513</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2021/rheumatoid-arthritis.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Targeting hormone receptors reduces lupus-related kidney damage in mice</title>
                    <description>Researchers at the University of California, Riverside, and City of Hope have identified a new strategy for treating systemic lupus erythematosus (SLE), or lupus, an autoimmune disease in which the immune system attacks healthy tissues. By targeting an imbalance in receptors for the hormone prolactin in disease-causing immune cells, the team reduced inflammatory molecules and harmful immune cells while preserving their normal counterparts.</description>
                    <link>https://medicalxpress.com/news/2026-11-hormone-receptors-lupus-kidney-mice.html</link>
                    <category></category>
                    <pubDate>Mon, 02 Nov 2026 15:40:06 EST</pubDate>
                    <guid isPermaLink="false">news712846797</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/new-strategy-identifie-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Long-term follow-up tracks benefits and risks of stem cell transplants for severe systemic sclerosis</title>
                    <description>An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation, adding evidence of sustained positive clinical outcomes and long-term safety in patients treated for early severe systemic sclerosis.</description>
                    <link>https://medicalxpress.com/news/2026-10-term-tracks-benefits-stem-cell.html</link>
                    <category></category>
                    <pubDate>Thu, 29 Oct 2026 19:30:01 EDT</pubDate>
                    <guid isPermaLink="false">news712477832</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2024/surgeon-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Mutated immune cells raise red flags in lupus</title>
                    <description>Scientists at La Jolla Institute for Immunology (LJI) and the University of Washington (UW) have discovered that patients with lupus have unusual mutations that may turn their bodies into battlegrounds.</description>
                    <link>https://medicalxpress.com/news/2026-10-mutated-immune-cells-red-flags.html</link>
                    <category></category>
                    <pubDate>Wed, 28 Oct 2026 18:00:06 EDT</pubDate>
                    <guid isPermaLink="false">news712424904</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2023/cells-2.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>How dismissed symptoms can push patients to breaking point</title>
                    <description>Patients have been left feeling suicidal after feeling like their doctor was saying their symptoms were &#039;all in their head&#039;—according to research from the University of East Anglia and the University of Cambridge.</description>
                    <link>https://medicalxpress.com/news/2026-10-dismissed-symptoms-patients.html</link>
                    <category></category>
                    <pubDate>Mon, 26 Oct 2026 20:10:05 EDT</pubDate>
                    <guid isPermaLink="false">news712216058</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/doctor-appointment.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Biomarkers identified for cytokine release syndrome risk after CAR T-cell therapy</title>
                    <description>For patients with autoimmune disease, higher baseline B-cell counts and systemic inflammation are associated with development of cytokine release syndrome (CRS) after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the November issue of The Lancet Rheumatology.</description>
                    <link>https://medicalxpress.com/news/2026-10-biomarkers-cytokine-syndrome-car-cell.html</link>
                    <category></category>
                    <pubDate>Mon, 26 Oct 2026 14:20:19 EDT</pubDate>
                    <guid isPermaLink="false">news712235170</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2023/biomarker-research.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Remission achievable with usual care for axial spondyloarthritis</title>
                    <description>For patients with axial spondyloarthritis (axSpA), remission is attainable with usual care, according to a study published in the Journal of Rheumatology.</description>
                    <link>https://medicalxpress.com/news/2026-10-remission-usual-axial-spondyloarthritis.html</link>
                    <category></category>
                    <pubDate>Mon, 26 Oct 2026 11:20:10 EDT</pubDate>
                    <guid isPermaLink="false">news712226327</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/back-pain-2.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Patient-reported outcomes worse for patients with rheumatoid arthritis discontinuing TNF inhibitor</title>
                    <description>For patients with rheumatoid arthritis (RA), patient-reported outcomes (PROs) generally worsen shortly after tumor necrosis factor inhibitor (TNFi) discontinuation, according to a study published in the Journal of Rheumatology.</description>
                    <link>https://medicalxpress.com/news/2026-10-patient-outcomes-worse-patients-rheumatoid.html</link>
                    <category></category>
                    <pubDate>Mon, 26 Oct 2026 11:00:29 EDT</pubDate>
                    <guid isPermaLink="false">news712226324</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2022/rheumatoid-arthritis.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Favorable long-term outcomes seen with treat-to-target strategy in early rheumatoid arthritis</title>
                    <description>For patients with early rheumatoid arthritis (RA) managed with a treat-to-target strategy, achievement of sustained remission at two years is associated with higher remission rates and better physical function at 10 years, according to a study published online Oct. 15 in Annals of the Rheumatic Diseases.</description>
                    <link>https://medicalxpress.com/news/2026-10-favorable-term-outcomes-strategy-early.html</link>
                    <category></category>
                    <pubDate>Tue, 20 Oct 2026 22:20:09 EDT</pubDate>
                    <guid isPermaLink="false">news711732181</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2021/rheumatoid-arthritis.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Increased risk for long COVID associated with autoimmune rheumatic diseases</title>
                    <description>Patients with autoimmune rheumatic diseases (AIRD) have an increased risk for long COVID, according to a study published online Oct. 14 in Arthritis &amp; Rheumatology.</description>
                    <link>https://medicalxpress.com/news/2026-10-covid-autoimmune-rheumatic-diseases.html</link>
                    <category></category>
                    <pubDate>Tue, 20 Oct 2026 21:40:06 EDT</pubDate>
                    <guid isPermaLink="false">news711732061</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/long-covid.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Autoimmune disease risk may differ by menopausal hormone therapy formulation</title>
                    <description>Progestogen, when used in hormone therapy, is recognized for its benefits in protecting the uterus. A new study suggests that its addition limits the increased risk of composite autoimmune disease associated with estrogen-only therapy. Results of the study were presented at the 2026 Annual Meeting of The Menopause Society in San Diego, Oct. 20–24, 2026.</description>
                    <link>https://medicalxpress.com/news/2026-10-autoimmune-disease-differ-menopausal-hormone.html</link>
                    <category></category>
                    <pubDate>Tue, 20 Oct 2026 10:20:01 EDT</pubDate>
                    <guid isPermaLink="false">news711697035</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/menopause-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>How psychological stress can trigger arthritis flares via an inflammatory pathway</title>
                    <description>Psychological stress has long been associated with worsening symptoms in rheumatoid arthritis (RA). However, the underlying mechanism connecting psychological stress to the occurrence of joint inflammation has remained poorly understood. In particular, how psychological stress can trigger inflammation in joints that were previously affected, even after the disease has gone into remission, remains an important unanswered question.</description>
                    <link>https://medicalxpress.com/news/2026-10-psychological-stress-trigger-arthritis-flares.html</link>
                    <category></category>
                    <pubDate>Fri, 16 Oct 2026 14:00:10 EDT</pubDate>
                    <guid isPermaLink="false">news711300001</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/how-psychological-stre.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Can we take the STING out of bone loss? Pathway presents potential treatment target for skeletal aging</title>
                    <description>As we age, our bones become weak and brittle, a process called osteoporosis. This bone loss is caused by changes in the cells within the bone marrow microenvironment, such as elevated fat and inflammation-promoting immune cells. One molecular driver of inflammation is the STING signaling pathway, though the role of this pathway in aging bones has until now been unclear.</description>
                    <link>https://medicalxpress.com/news/2026-10-bone-loss-pathway-potential-treatment.html</link>
                    <category></category>
                    <pubDate>Thu, 15 Oct 2026 03:10:01 EDT</pubDate>
                    <guid isPermaLink="false">news711201542</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2023/osteoporosis.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Simple, noninvasive technique can assess collagen in the skin of scleroderma patients</title>
                    <description>Scleroderma (systemic sclerosis) is a rare, chronic autoimmune disease that causes the body to produce too much collagen, leading to the hardening and thickening of the skin and internal organs. For more than 50 years, physicians have relied on manually pinching the skin to assess its thickness, a subjective approach that remains central to the diagnosis of systemic sclerosis, assessment of disease extent and progression and monitoring of response to treatment.</description>
                    <link>https://medicalxpress.com/news/2026-10-simple-noninvasive-technique-collagen-skin.html</link>
                    <category></category>
                    <pubDate>Wed, 14 Oct 2026 18:30:34 EDT</pubDate>
                    <guid isPermaLink="false">news711206041</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/inflammed-skin.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Early axial spondyloarthritis diagnosis linked to lower long-term spinal damage</title>
                    <description>Early axial spondyloarthritis (axSpA), with a duration of no more than two years of axial symptoms, is associated with lower long-term spinal structural damage, according to a study published online Sept. 18 in Arthritis &amp; Rheumatology.</description>
                    <link>https://medicalxpress.com/news/2026-10-early-axial-spondyloarthritis-diagnosis-linked.html</link>
                    <category></category>
                    <pubDate>Tue, 13 Oct 2026 15:20:18 EDT</pubDate>
                    <guid isPermaLink="false">news711114027</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2022/spine.jpg" width="90" height="90" />
                                    </item>
                    </channel>
</rss>
